MAA
NBIX icon

Managed Account Advisors’s Neurocrine Biosciences NBIX Stock Holding History

Managed Account Advisors’s Portfolio NBIX Stock Details NBIX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2015
Q2 		$3.83M Buy
80,130
+9,055
+13% +$384K ﹤0.01% 1548
2015
Q1 		$2.82M Buy
71,075
+50,662
+248% +$1.81M ﹤0.01% 1692
2014
Q4 		$456K Sell
20,413
-762
-4% -$14.4K ﹤0.01% 2219
2014
Q3 		$332K Buy
21,175
+3,190
+18% +$47.7K ﹤0.01% 2246
2014
Q2 		$267K Sell
17,985
-4,122
-19% -$58.2K ﹤0.01% 2243
2014
Q1 		$356K Buy
+22,107
New +$378K ﹤0.01% 2151

Other funds holding NBIX

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
BB
BB Biotech Schaffhausen, Switzerland $3.98B AUM 15.47% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
PC
PointState Capital New York $7.9B AUM 42.31% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Managed Account Advisors's NBIX Position: Q2 2015 in Review

Managed Account Advisors increased its Neurocrine Biosciences (NBIX) stake by 13% in Q2 2015, buying an estimated $384K and bringing the position to 80,130 shares worth $3.83M. The position accounts for ﹤0.01% of the portfolio, ranked #1548.

Managed Account Advisors first reported a position in NBIX in Q1 2014 and has held it in 6 quarters since. 198 funds tracked by Wall St. Rank hold NBIX as of Q2 2015.

  • Managed Account Advisors held 80,130 shares of Neurocrine Biosciences worth $3.83M as of Q2 2015.
  • Managed Account Advisors bought 9,055 Neurocrine Biosciences shares in Q2 2015, an estimated $384K.
  • Neurocrine Biosciences made up ﹤0.01% of Managed Account Advisors's portfolio in Q2 2015, its #1548 holding.
  • Managed Account Advisors first reported a position in Neurocrine Biosciences in Q1 2014 and has held it in 6 quarters since.
  • 198 funds tracked by Wall St. Rank held Neurocrine Biosciences as of Q2 2015.

Based on Managed Account Advisors's 13F filing for Q2 2015, filed 14 Aug 2015.